Table 4.
Intervention Effects on Additional Breast Cancer Events by Baseline Clinical and Demographic Characteristics
| No./Total |
||||
|---|---|---|---|---|
| Intervention | Comparison | HR (95% CI)a | P Valueb | |
| Age at randomization, y | ||||
| <55 | 167/908 | 161/917 | 1.05 (0.84–1.30) | .35 |
| ≥55 | 89/629 | 101/634 | 0.89 (0.67–1.18) | |
| Cancer stage at diagnosis | ||||
| I | 50/585 | 55/606 | 0.94 (0.64–1.38) | |
| II | 178/876 | 182/867 | 0.97 (0.79–1.19) | .74 |
| IIIA | 28/76 | 25/78 | 1.19 (0.69–2.04) | |
| Hormone receptor statusc | ||||
| ER+/PR+ | 140/955 | 145/948 | 0.95 (0.76–1.20) | |
| ER+/PR− | 37/197 | 32/169 | 0.97 (0.60–1.56) | .85 |
| ER−/PR+ | 11/52 | 18/77 | 0.89 (0.42–1.88) | |
| ER−/PR− | 64/300 | 62/319 | 1.14 (0.80–1.61) | |
| Time from diagnosis to randomization, y | ||||
| ≤1 | 59/352 | 65/350 | 0.88 (0.62–1.26) | |
| >1 to 2 | 83/488 | 90/508 | 0.95 (0.71–1.28) | .50 |
| >2 to 3 | 64/375 | 52/372 | 1.26 (0.87–1.82) | |
| >3 to 4 | 50/322 | 55/321 | 0.90 (0.61–1.32) | |
| Tumor differentiation | ||||
| I (well differentiated) | 20/239 | 22/245 | 0.90 (0.49–1.65) | |
| II (moderately differentiated) | 94/620 | 100/620 | 0.93 (0.70–1.24) | .75 |
| III (poorly differentiated) | 121/551 | 114/557 | 1.09 (0.85–1.41) | |
| Unspecified | 21/127 | 26/129 | 0.83 (0.47–1.48) | |
| No. of positive nodesc | ||||
| 0 | 93/879 | 117/896 | 0.80 (0.61–1.06) | |
| 1–3 | 83/436 | 69/448 | 1.25 (0.91–1.72) | .07 |
| 4–6 | 39/116 | 31/115 | 1.29 (0.80–2.06) | |
| ≥7 | 41/105 | 45/92 | 0.75 (0.49–1.15) | |
| Tumor size, cmc | ||||
| 0 to <2 | 82/752 | 88/769 | 0.94 (0.70–1.28) | |
| 2 to <3 | 88/421 | 86/441 | 1.09 (0.81–1.47) | |
| 3 to <4 | 30/174 | 41/160 | 0.62 (0.39–1.00) | .22 |
| 4 to <5 | 21/79 | 20/72 | 0.90 (0.49–1.67) | |
| ≥5 | 35/109 | 27/106 | 1.32 (0.80–2.18) | |
| Body mass indexd | ||||
| <25 | 107/652 | 112/678 | 0.99 (0.76–1.29) | |
| 25 to <30 | 81/475 | 68/480 | 1.22 (0.88–1.69) | .17 |
| ≥30 | 68/410 | 82/393 | 0.79 (0.57–1.09) | |
| Physical activity, MET-min/wkc | ||||
| ≤210 | 68/397 | 66/350 | 0.90 (0.64–1.27) | |
| 211–615 | 62/368 | 71/383 | 0.91 (0.64–1.27) | .56 |
| 616–1290 | 65/375 | 54/374 | 1.22 (0.85–1.74) | |
| >1290 | 49/351 | 60/387 | 0.88 (0.60–1.28) | |
| Energy intake, kcal/dc | ||||
| ≤1430 | 63/377 | 73/396 | 0.89 (0.64–1.25) | |
| 1431–1680 | 59/384 | 64/386 | 0.90 (0.63–1.28) | .69 |
| 1681–1980 | 64/390 | 54/379 | 1.16 (0.81–1.66) | |
| >1980 | 70/383 | 70/386 | 1.04 (0.75–1.45) | |
Abbreviations: CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; MET, metabolic equivalent task; PR, progesterone receptor.
a
Hazard ratios of group effect were derived from Cox model stratified by covariate categories.
b
P values based on likelihood ratio test for group X covariate interaction.
c
Numbers do not total 3088 because of missing data.
d
Calculated as weight in kilograms divided by height in meters squared.